GSK outlines rare disease strategy
This article was originally published in Scrip
Having announced back in February that it was establishing a specific business unit to build a rare diseases franchise, GlaxoSmithKline is beginning to reveal what its focus and approach will be. Dr Shelagh Wilson, vice-president of business development, GSK Rare Diseases, spoke exclusively to Scrip following her presentation at BioPartnering Europe in London this week.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.